Investing.com – JPMorgan initiated coverage on Seaport Therapeutics (NASDAQ:SPTX) with an overweight rating and a price target of $42.00. The stock currently trades at $17.50, representing significant upside to the analyst’s target, with the company commanding a market capitalization of $928 million.
Analyst Tessa Romero cited the company’s Glyph platform, which redirects drugs to the lymphatic system to avoid first-pass metabolism. The platform advances active drugs previously limited by low oral bioavailability, hepatotoxicity, and side effects.
The company focuses on neuropsychiatry with lead programs GlyphAllo and GlyphAgo. These are Glyphed formulations of allopregnanolone and agomelatine, which have shown varying degrees of proof-of-mechanism and clinical proof-of-concept in major depressive disorder and generalized anxiety disorder.
JPMorgan said prior results reduce clinical risk in these indications to some degree. The firm noted neuropsychiatry trials remain associated with higher inherent risk overall, balanced by the platform’s advantages and management expertise. The company maintains a strong financial position with liquid assets exceeding short-term obligations by a current ratio of 17.46, though it remains unprofitable with an EPS of -$10.04 over the last twelve months. According to InvestingPro, which offers access to over 10 additional exclusive tips and comprehensive financial metrics, the stock has delivered an 11.75% return over the past week.
JPMorgan said both drugs could be significant value-drivers with blockbuster sales potential if successful. The firm sees an attractive entry point in the stock at current levels.
In other recent news, Seaport Therapeutics has successfully priced its initial public offering at $18 per share. The company sold 14,160,000 shares, achieving the top of its target range and expecting to receive gross proceeds of approximately $254.9 million. This figure is before accounting for underwriting discounts, commissions, and offering expenses. Additionally, Seaport Therapeutics has provided underwriters a 30-day option to purchase an extra 2,124,000 shares at the IPO price. In related developments, Goldman Sachs has initiated coverage on Seaport Therapeutics, assigning it an Early-Stage Biotech rating. These events mark significant milestones for the company as it moves forward in the financial markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.